EASD 2026 Obesity Data Roundup: EloraTZP, Petrelintide, Retatrutide & CagriSema
EASD 2026 amylin and incretin data in one place: EloraTZP up to 23.3% at 48 weeks, petrelintide up to 10.7% at 42 weeks, retatrutide TRIUMPH-2 up to 20.8% at 80 weeks, plus CagriSema analyses.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
EASD 2026 amylin and incretin peptide data brought four major sponsor-reported readouts to the 62nd Annual Meeting in Milan (September 28 to October 2, 2026): the petrelintide ZUPREME-1 Phase 2 results, the Phase 2b EloraTZP (eloralintide plus tirzepatide) results, the full TRIUMPH-2 retatrutide dataset, and several CagriSema late-breaking analyses. This roundup summarizes only what sponsors and journals have published, and links each compound to its research profile.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: The main EASD 2026 incretin and amylin disclosures were petrelintide's ZUPREME-1 Phase 2 results (up to 10.7% mean weight loss versus 1.7% for placebo at week 42), Lilly's EloraTZP amylin-plus-tirzepatide combination (up to 23.3% at 48 weeks versus 14.8% for tirzepatide 15 mg in type 2 diabetes plus obesity), full TRIUMPH-2 results for retatrutide (up to 20.8% at 80 weeks in type 2 diabetes plus obesity), and CagriSema organ and bone sub-analyses.
TL;DR:
- Petrelintide: ZUPREME-1 (NCT06662539) published in The Lancet Diabetes & Endocrinology, with an EASD oral presentation on September 30.
- EloraTZP (eloralintide + tirzepatide): a 48-week Phase 2b trial in 367 adults with type 2 diabetes reported up to 23.3% weight reduction and up to 2.9-point HbA1c reduction; Lilly plans Phase 3 by end of 2026.
- Retatrutide: TRIUMPH-2 reported 12.7%, 19.1% and 20.8% weight reduction (efficacy estimand) at 4, 9 and 12 mg versus 4.0% for placebo.
- CagriSema: new late-breaking analyses covered food-noise, liver and pancreas fat, and bone markers.
- Regulatory milestones cited by sponsors: a retatrutide BLA planned for Q1 2027 and a CagriSema NDA decision expected in Q4 2026.
- All results below are sponsor-reported or journal-published; none of these compounds are approved for the indications studied unless stated.
Petrelintide: ZUPREME-1 results and publication
Zealand Pharma announced on September 29, 2026 that the Phase 2 ZUPREME-1 trial (NCT06662539) of petrelintide was published in The Lancet Diabetes & Endocrinology and would be presented orally at EASD on September 30. According to the release, the trial enrolled 485 participants across once-weekly subcutaneous doses of 1.0 to 9.0 mg, and the highest-performing arm reached up to 10.7% mean body weight loss at week 42 versus 1.7% with placebo.
| Item | Detail |
|---|---|
| Trial | ZUPREME-1, Phase 2 (NCT06662539) |
| Result | Up to 10.7% vs 1.7% placebo, week 42 |
| Source | Sponsor release, September 29, 2026; Lancet Diabetes & Endocrinology |
Earlier human pharmacology for the molecule is described in the Phase 1 report, PMID 42017294: "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials" (Diabetes, Obesity and Metabolism, 2026). A detailed head-to-head framing against the other long-acting amylin analogue in Phase 2 development is available in the petrelintide vs eloralintide comparison.
Eloralintide plus tirzepatide (EloraTZP): Phase 2b results
Eli Lilly reported on September 30, 2026 that a 48-week Phase 2b trial of EloraTZP, the combination of the selective amylin receptor agonist eloralintide with the GIP/GLP-1 receptor agonist tirzepatide, was presented at EASD. The trial enrolled 367 adults with obesity or overweight and type 2 diabetes (baseline HbA1c 8.1%) and compared several combination doses with each drug alone and with placebo.
| Arm (48 wk, efficacy estimand) | Weight change | HbA1c change |
|---|---|---|
| Eloralintide 9 mg + tirzepatide 15 mg | -23.3% | -2.9 points |
| Eloralintide 6 mg + tirzepatide 10 mg | -19.9% | -2.6 points |
| Eloralintide 6 mg + tirzepatide 5 mg | -19.4% | -2.7 points |
| Eloralintide 3 mg + tirzepatide 5 mg | -13.2% | -2.2 points |
| Tirzepatide 15 mg alone | -14.8% | -2.4 points |
| Eloralintide 6 mg alone | -12.3% | -1.4 points |
| Placebo | -3.0% | -0.3 points |
Tolerability is the open question. According to the release, gastrointestinal events were more frequent in the combination arms, mostly during dose escalation, and discontinuation due to adverse events ranged from 10.8% to 27.0% with EloraTZP versus 2.9% with tirzepatide alone. Lilly stated it plans to start Phase 3 trials of a co-formulated product by the end of 2026, using an optimized escalation schedule. Eloralintide is already in Phase 3 as a single agent.
The earlier monotherapy evidence is the 48-week Phase 2 trial reported in The Lancet: PMID 41207310, "Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial" (The Lancet, 2025). Researchers comparing it with the cagrilintide-based approach can consult the eloralintide vs cagrilintide comparison.
Retatrutide: TRIUMPH-2 full results
Eli Lilly reported on September 29, 2026 that full TRIUMPH-2 results for retatrutide were presented at EASD and published in The Lancet. The trial enrolled 1,152 adults with type 2 diabetes and obesity. At 80 weeks, the efficacy-estimand mean weight reduction was 12.7%, 19.1% and 20.8% at 4 mg, 9 mg and 12 mg, versus 4.0% with placebo. Mean HbA1c fell by 1.4, 1.6 and 1.5 percentage points from a baseline of 7.7%. The sponsor stated that a Biologics License Application is planned for the first quarter of 2027.
| Dose | Weight change (80 wk, efficacy estimand) | HbA1c change |
|---|---|---|
| 4 mg | -12.7% | -1.4 points |
| 9 mg | -19.1% | -1.6 points |
| 12 mg | -20.8% | -1.5 points |
| Placebo | -4.0% | not stated here |
Context on the TRIUMPH-1 and TRIUMPH-3 readouts is covered in the retatrutide Phase 3 results article. The triple GIP/GLP-1/glucagon mechanism is profiled in the library entry above; the stored primary citation for that profile is a rodent receptor study, so human efficacy figures here come from the sponsor release rather than that record.
CagriSema and cagrilintide: EASD late-breakers
Novo Nordisk reported on September 30, 2026 several late-breaking analyses of CagriSema, the fixed combination of cagrilintide and semaglutide. As described in the release:
- A 52-week food-noise study using functional MRI reported a 22.4% weight reduction versus placebo (estimated treatment difference).
- A REIMAGINE 1 MRI sub-study reported 14.3% weight reduction at week 40, with reduced liver and pancreas fat.
- A REIMAGINE 2 post hoc analysis of bone markers accompanied 14.2% weight reduction at week 68.
The sponsor stated that a regulatory decision on the combination is expected in the fourth quarter of 2026. The pivotal program is described in PMID 40544433, "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1)" (New England Journal of Medicine, 2025), DOI https://doi.org/10.1056/NEJMoa2502081. Further cagrilintide context appears in the cagrilintide vs semaglutide comparison.
Other glucagon-axis compounds in the research landscape
Mazdutide and survodutide are GLP-1/glucagon dual agonists that were not the subject of the sponsor releases summarized above, but they sit alongside retatrutide in the same receptor-pharmacology conversation. Published records include PMID 38092790, "A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity" (Nature Communications, 2023) and PMID 41187967, "Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE-1)" (Diabetes, Obesity and Metabolism, 2026). Additional comparisons include the mazdutide vs tirzepatide analysis and the VK2735 vs semaglutide comparison.
What changed relative to earlier 2026 meetings
| Compound | Earlier 2026 position | EASD 2026 update |
|---|---|---|
| Petrelintide | Phase 2 topline announced by sponsor (March 2026) | Peer-reviewed publication and oral presentation |
| Eloralintide | Phase 2 monotherapy published (The Lancet, 2025) | Phase 2b combination with tirzepatide; Phase 3 planned by end of 2026 |
| Retatrutide | Phase 3 TRIUMPH-1 and -3 readouts | TRIUMPH-2 full results, BLA timeline stated |
| CagriSema | REDEFINE 1 published | Food-noise, organ-fat and bone-marker analyses |
Researchers following registered trials by phase and sponsor can use the trial tracker to see the status of each program.
Cited studies
- PMID 42017294: "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials" (Diabetes, Obesity and Metabolism, 2026). https://doi.org/10.1111/dom.70753
- PMID 41207310: "Eloralintide, a selective amylin receptor agonist for the treatment of obesity" (The Lancet, 2025). https://doi.org/10.1016/S0140-6736(25)02155-5
- PMID 40544433, "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1)" (New England Journal of Medicine, 2025). https://doi.org/10.1056/NEJMoa2502081
- PMID 38092790, "A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity" (Nature Communications, 2023). https://doi.org/10.1038/s41467-023-44067-4
- PMID 41187967, "Survodutide for treatment of obesity: Baseline characteristics (SYNCHRONIZE-1)" (Diabetes, Obesity and Metabolism, 2026). https://doi.org/10.1111/dom.70196
External sources
- Zealand Pharma press release, September 29, 2026 (ZUPREME-1 publication and EASD presentation): https://www.globenewswire.com/news-release/2026/09/29/3371443/0/en/zealand-pharma-to-present-additional-data-from-phase-2-zupreme-1-trial-for-petrelintide-at-easd-2026-and-announces-publication-of-trial-results-in-the-lancet-diabetes-endocrinology.html
- Eli Lilly press release, September 29, 2026 (TRIUMPH-2): https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-substantial-weight
- Eli Lilly press release, September 30, 2026 (EloraTZP Phase 2b): https://www.biospace.com/press-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes
- Novo Nordisk press release, September 30, 2026 (CagriSema EASD late-breakers): https://www.globenewswire.com/news-release/2026/09/30/3371858/0/en/novo-s-investigational-obesity-and-diabetes-drug-cagrisema-reduces-food-noise-and-shows-benefits-in-organ-and-bone-health-easd-2026.html
Frequently asked questions
Q: When and where was EASD 2026 held?
A: The 62nd Annual Meeting of the European Association for the Study of Diabetes took place in Milan, Italy, from September 28 to October 2, 2026. Sponsors released several incretin and amylin datasets during that week.
Q: What did the petrelintide EASD 2026 data show?
A: Zealand Pharma reported that ZUPREME-1 (NCT06662539), a Phase 2 trial, showed up to 10.7% mean weight loss versus 1.7% with placebo at week 42. The results were published in The Lancet Diabetes & Endocrinology and presented orally on September 30.
Q: What is EloraTZP and what did it show at EASD 2026?
A: EloraTZP is Lilly's investigational combination of eloralintide (a selective amylin receptor agonist) and tirzepatide. In a 48-week Phase 2b trial in 367 adults with type 2 diabetes and obesity or overweight, the highest dose produced 23.3% mean weight reduction versus 14.8% with tirzepatide 15 mg alone, with HbA1c reductions up to 2.9 points. Discontinuation due to adverse events was higher with the combination (10.8% to 27.0%).
Q: What were the TRIUMPH-2 retatrutide results?
A: Lilly reported 80-week efficacy-estimand weight reductions of 12.7%, 19.1% and 20.8% at 4, 9 and 12 mg versus 4.0% with placebo in adults with type 2 diabetes and obesity. HbA1c fell by 1.4 to 1.6 percentage points from a 7.7% baseline.
Q: What is CagriSema and what was new at EASD 2026?
A: CagriSema is a fixed combination of cagrilintide and semaglutide. Novo Nordisk presented analyses of food-noise outcomes, liver and pancreas fat on MRI, and bone markers from the REIMAGINE program.
Q: Are these compounds approved?
A: Petrelintide, eloralintide, EloraTZP and retatrutide are investigational and not approved. Sponsors have stated a retatrutide BLA is planned for Q1 2027 and that a CagriSema regulatory decision is expected in Q4 2026; timelines may change.
See also:
- Petrelintide vs eloralintide: head-to-head of two long-acting amylin analogues
- Eloralintide vs cagrilintide: selective amylin versus cagrilintide-based research
- Retatrutide Phase 3 results: TRIUMPH-1, -2 and -3 data
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.